Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aethlon Medical (AEMD)

Aethlon Medical (AEMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Financial Summary for [[ item.sessionDateDisplayLong ]]
Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.

Fiscal Year End Date: 03/31

(Values in U.S. Thousands) Sep, 2025 Jun, 2025 Mar, 2025 Dec, 2024 Sep, 2024
Sales 0 0 0 0 0
Sales Growth unch unch unch unch unch
Net Income -1,490 -1,760 -6,250 -1,750 -2,810
Net Income Growth +15.34% +71.84% -257.14% +37.72% -9.34%
(Values in U.S. Thousands) Sep, 2025 Jun, 2025 Mar, 2025 Dec, 2024 Sep, 2024
Total Assets 7,320 5,310 7,360 6,530 8,850
Total Assets Growth +37.85% -27.85% +12.71% -26.21% -22.50%
Total Liabilities 1,580 1,880 2,240 2,190 2,830
Total Liabilities Growth -15.96% -16.07% +2.28% -22.61% +4.81%
(Values in U.S. Thousands) Sep, 2025 Jun, 2025 Mar, 2025 Dec, 2024 Sep, 2024
Operating Cash Flow -3,370 -1,710 -7,650 -5,970 -3,960
Operating Cash Flow Growth -97.08% +77.65% -28.14% -50.76% -126.29%
Net Cash Flow 350 -1,740 70 -620 1,420
Change in Net Cash Flow +120.11% -2,585.68% +111.29% -143.66% -60.88%
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar